Bookbot

Multiple Sclerosis

Advances in Clinical Trial Design, Treatment and Future Perspectives

Więcej o książce

Multiple Advances in Clinical Trial Design, Treatment and Future Perspectives is a review of therapeutic developments for a disease that is one of the major problems in current neurologic practice. Progress in this field has been rapid and there have been important developments in clinical trial design and a number of important trial results that have resulted in new treatment options for patients and physicians. Important ethical considerations that arise with new treatments are included, as is a perspective on the emergence of MS as a treatable disease. This book is for all neurologists, primary care physicians, and patients concerned about the treatment of MS. It will also be of value to clinical epidemiologists and biostatisticians with an interest in experimental therapies for chronic disease, to immunologists with an interest in autoimmune disease, to the pharmaceutical industry and to MS societies.

Zakup książki

Multiple Sclerosis, Donald E. Goodkin, Richard A. Rudick

Język
Rok wydania
1997
Oprawa
(twarda)
Jak tylko się pojawi, wyślemy Ci wiadomość e-mail.

Metody płatności

Nikt jeszcze nie ocenił.Oceń

Tytuł
Multiple Sclerosis
Podtytuł
Advances in Clinical Trial Design, Treatment and Future Perspectives
Język
angielski
Wydawca
Springer
Rok wydania
1997
Oprawa
twarda
Liczba stron
364
ISBN10
3540760180
ISBN13
9783540760184
Seria
Opis
Multiple Advances in Clinical Trial Design, Treatment and Future Perspectives is a review of therapeutic developments for a disease that is one of the major problems in current neurologic practice. Progress in this field has been rapid and there have been important developments in clinical trial design and a number of important trial results that have resulted in new treatment options for patients and physicians. Important ethical considerations that arise with new treatments are included, as is a perspective on the emergence of MS as a treatable disease. This book is for all neurologists, primary care physicians, and patients concerned about the treatment of MS. It will also be of value to clinical epidemiologists and biostatisticians with an interest in experimental therapies for chronic disease, to immunologists with an interest in autoimmune disease, to the pharmaceutical industry and to MS societies.